FindMyKOL

Mihran Shirinian, MD

Basic profile

Adventist Health Glendale

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionGlendale, CA · WestSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Mihran Shirinian is an Oncology physician affiliated with Adventist Health Glendale. OpenAlex indexes 17 publications with 1,042 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
17publications

Publications indexed by OpenAlex. Counts exclude supporting files.

1,042citations

Citations across these publications.

10h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
28companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Janssen
    Program year20251 paymentResearch
    $44,200
  • Caris MPI
    Program year20251 paymentResearch
    $26,000
  • AstraZeneca
    Program year20251 paymentResearch
    $16,500
All 62 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    66.5%
    PD-1 inhibitor28.9%
    Pembrolizumab100%Keytruda1%
    Part D + Part B≥21 patients
    Platinum-based Drug23.7%
    Oxaliplatin98%Carboplatin2%
    Part B, office-administered≥17 patients

    + 16 more classes in this area

  • Metabolism & gastrointestinal

    16.9%
    Serotonin-3 Receptor Antagonist16.6%
    Ondansetron hydrochloride99%Ondansetron Odt1%
    Part D + Part B≥81 patients
    Substance P/Neurokinin-1 Receptor Antagonist0.2%
    Aprepitant93%Emend7%
    Part D<11 patients

    + 5 more classes in this area

  • Blood & clotting

    11%
    Parenteral Iron Replacement9.2%
    Iron sucrose100%
    Part B, office-administered≥18 patients
    Erythropoiesis-stimulating Agent1.5%
    Epoetin alfa99%Procrit1%
    Part D + Part B<11 patients

    + 5 more classes in this area

Where care is delivered (Part B)2.1% facility · 97.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”